(London, UK: 1996), p. 618.
3. Keezer, S. M., et al., Angiogenesis inhibitors target
the endothelial cell cytoskeleton through altered
regulation of heat shock protein 27 and cofilin.
Cancer Res
1989).
8. Barman, T.E., Enzyme Handbook, Vol. II.
Springer-Verlag (New York, NY), pp. 618-619
(1969).
9. United States Pharmacopoeia (USP) XXIII,
p. 1611 (2000).
10. Wang, S.-S., and Carpenter
Biotechnol.,
4(5), 520-525 (1993).
6. Jarvik, W., and Telmer, C.A., Annu. Rev. Genet.,
32, 601-618 (1998).
7. Campbell, A. et al., J. Biol. Chem., 267(13),
9321-9325 (1992).
8. Royds, J.A.
pluripotency and directed
differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:
618–630.
27. Bielby RC, Boccaccini AR, Polak JM, Buttery LD (2004) In vitro differentiation and
in vivo mineralization
Phosphatase
Profiler™ Service
Calcineurin/PP2B, active 14-390
Calcineurin/PP2B, active 14-446
CD45 14-618 3
cdc25A, active 14-369
cdc25B, active 14-370
DUSP22 14-641 3
HePTP 14-593 3
Lambda Protein Phosphatase
pluripotency and direct differentiation of human
cells with synthetic modified mRNA. Cell Stem Cell 7(5):618-630.
3. Yoshioka, N., et. al. (2013). Efficient Generation of human iPSCs by a synthetic self-replicative
pluripotency and direct differentiation of human
cells with synthetic modified mRNA. Cell Stem Cell 7(5):618-630.
3. Yoshioka, N., et. al. (2013). Efficient Generation of human iPSCs by a synthetic self-replicative
001018125.1 ,NP_149075.2 y n/d n/d
618 Pyk2 P3902 2185 PTK2B P NP_004094.3 y y y
620 phospho-Pyk2 (pTyr579/580) P6989 2185 PTK2B P NP_004094.3 y n/d n/d
273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1
001018125.1 ,NP_149075.2 y n/d n/d
618 Pyk2 P3902 2185 PTK2B P NP_004094.3 y y y
620 phospho-Pyk2 (pTyr579/580) P6989 2185 PTK2B P NP_004094.3 y n/d n/d
273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1
001018125.1 ,NP_149075.2 y n/d n/d
618 Pyk2 P3902 2185 PTK2B P NP_004094.3 y y y
620 phospho-Pyk2 (pTyr579/580) P6989 2185 PTK2B P NP_004094.3 y n/d n/d
273 Fibroblast Growth Factor-9 F1672 2254 FGF9 M NP_002001.1
P3487 M y y y
616 PUMA/bbc3, C-Terminal P4618 P y y n/d
617 PUMA/bbc3, N-Terminal P4743 P y n/d n/d
618 Pyk2 P3902 P y y y
619 AP2 beta P7114 M y n/d n/d
620 phospho-Pyk2 (pTyr579/580) P6989 P y n/d n/d
_055232.1,NP_573497.1 P y y n/d
617 PUMA/bbc3, N-Terminal P4743 27113 BBC3 NP_055232.1 P y n/d n/d
618 Pyk2 P3902 50646, 2185, 19229 Ptk2b,PTK2B NP_059014.2,NP_775268.1,NP_766086.1 P y y y
619 phospho-Pyk2
, 97%, FCC, FG W245615 B83651 HC-23SI5Q28
617. ETHYL PYRUVATE 97% W245704 A23535 HC-23SI3U04
618. ETHYL PYRUVATE NATURAL, 95%, FG W245712 A98244 HC-23SIKQ12
This is to certify that the following
, 97%, FCC, FG W245615 B83651 HC-22SI7649
617. ETHYL PYRUVATE 97% W245704 A23535 HC-22SI6X25
618. ETHYL PYRUVATE NATURAL, 95%, FG W245712 A98244 HC-22SISZ33
This is to certify that the following
Rb 100 µL AB1965
WAVE
Monoclonal Antibody
Anti-WAVE1/Scar1 84.79 R WB Ascites M IgG 200 µL 05-618
Polyclonal Antibody
Anti-WAVE/Scar H M R WB IP Pur Rb IgG 100 µg 07-037
Anti-WAVE2/Scar2 H